Compare Diamondback Energy Inc (FANG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Zoetis Inc — how do they compare? Diamondback Energy Inc trades at $192.03 (market cap $53.67B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Diamondback Energy Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and Zoetis Inc for 70 Days on average.
| FANG | ZTS | |
|---|---|---|
Market Cap | $53.67B | $30.20B |
Volume | 2,250,644 | 6,175,327 |
Sector | Energy | Health |
52-Week High | $213.69 | $147.53 |
52-Week Low | $137.29 | $69.09 |
Typical Hold Time | 69 Days | 70 Days |
Enterprise Value | $65.83B | $37.76B |
Dividend Yield | 2.3% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $192.30, up 4.3% today, showing strong momentum near its recent highs. The stock maintains a bullish technical outlook with solid fundamental support from growing revenue and consistent earnings beats. Recent Q2 2026 EPS of $6.48 exceeded expectations by 6.6%, while analyst consensus remains overwhelmingly positive with 90.6% buy ratings and a $231.77 price target. The company's cash flow generation remains robust with $8.76B from operations in 2025, supporting dividend payments and strategic investments.
FANG presents a compelling growth opportunity with strong Permian Basin positioning and improving operational efficiency, though investors should monitor oil price volatility and recent insider selling activity. The stock's current valuation at 36.5x P/E reflects growth expectations, while technical indicators suggest potential resistance near $195-$197 levels. With solid institutional support and positive industry outlook, FANG remains well-positioned for continued upside if execution remains strong.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
